BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 19.5] [Reference Citation Analysis]
Number Citing Articles
1 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Armentano DPD, Monteiro MR, Aguiar PN, Tsukamoto JS, Pio RB, Arakelian R, Araujo RLC, Usón PLS. Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments. einstein (São Paulo) 2022;20. [DOI: 10.31744/einstein_journal/2022ao6985] [Reference Citation Analysis]
3 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pundir M, Papagerakis S, De Rosa MC, Chronis N, Kurabayashi K, Abdulmawjood S, Prince MEP, Lobanova L, Chen X, Papagerakis P. Emerging biotechnologies for evaluating disruption of stress, sleep, and circadian rhythm mechanism using aptamer-based detection of salivary biomarkers. Biotechnology Advances 2022. [DOI: 10.1016/j.biotechadv.2022.107961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Galanis I, Simou M, Floros G. Large-Cell Esophageal Neuroendocrine Carcinoma: Report of a Rare Case. Cureus 2022. [DOI: 10.7759/cureus.22041] [Reference Citation Analysis]
7 Andreasi V, Partelli S, Manzoni MF, Muffatti F, Di Filippo L, Crippa S, Corti A, Falconi M. Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors. J Endocrinol Invest 2022. [PMID: 35122631 DOI: 10.1007/s40618-022-01750-5] [Reference Citation Analysis]
8 Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci 2022;23:1447. [PMID: 35163374 DOI: 10.3390/ijms23031447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 徐 新. Clinical Pathology, Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms. ACM 2022;12:4192-4200. [DOI: 10.12677/acm.2022.125608] [Reference Citation Analysis]
10 Zarkesh M, Arab N, Tavangar SM, Nozhat Z, Fanaei S, Hedayati M. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer. Pathology - Research and Practice 2022;229:153694. [DOI: 10.1016/j.prp.2021.153694] [Reference Citation Analysis]
11 Halperin R, Ahron-Hananel G, Badarna M, Greidinger D, Uri I, Percik R, Tirosh A. Plasma Hemoglobin and Red Blood Cell Mass Levels as Dynamic Prognostic Markers for Progression and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res 2021;53:810-7. [PMID: 34891211 DOI: 10.1055/a-1672-4653] [Reference Citation Analysis]
12 Tsai HJ, Hsiao CF, Chang JS, Chen LT, Chao YJ, Yen CJ, Shan YS. The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors - A Single-Center Experience. Front Oncol 2021;11:741096. [PMID: 34868938 DOI: 10.3389/fonc.2021.741096] [Reference Citation Analysis]
13 Weber DM, Yang JY, Goldman SM, Clarke NJ, Taylor SW, McPhaul MJ. Antibody-Free Quantification of Serum Chromogranin A by Targeted Mass Spectrometry. Clin Chem 2021;67:1618-27. [PMID: 34718463 DOI: 10.1093/clinchem/hvab191] [Reference Citation Analysis]
14 Deasy WAG, Cangara MH, Zainuddin AA, Achmad D, Wahid S, Miskad UA. The Expression of Chromogranin A, Syanptophysin and Ki67 in Detecting Neuroendocrine Neoplasma at High Grade Colorectal Adenocarcinoma. Open Access Maced J Med Sci 2021;9:1142-1147. [DOI: 10.3889/oamjms.2021.7419] [Reference Citation Analysis]
15 Snezhkina A, Pavlov V, Dmitriev A, Melnikova N, Kudryavtseva A. Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas. Life (Basel) 2021;11:1179. [PMID: 34833055 DOI: 10.3390/life11111179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Ehrlichman PD, Vijayvergia N. Unlocking the Code to Management of Neuroendocrine Neoplasms: A Clinician's Perspective. JCO Oncol Pract 2021;:OP2100628. [PMID: 34731030 DOI: 10.1200/OP.21.00628] [Reference Citation Analysis]
17 Mineur L, Boustany R, Vazquez L. Paraneoplastic Cushing Syndrome in Gastrointestinal Neuroendocrine Tumour. Case Rep Oncol 2021;14:1407-13. [PMID: 34720949 DOI: 10.1159/000518316] [Reference Citation Analysis]
18 Kalligeros M, Diamantopoulos L, Toumpanakis C. Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review. Biology (Basel) 2021;10:950. [PMID: 34681049 DOI: 10.3390/biology10100950] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Juhlin CC. Second-Generation Neuroendocrine Immunohistochemical Markers: Reflections from Clinical Implementation. Biology (Basel) 2021;10:874. [PMID: 34571751 DOI: 10.3390/biology10090874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
20 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
21 Geisler L, Mohr R, Lambrecht J, Knorr J, Jann H, Loosen SH, Özdirik B, Luedde T, Hammerich L, Tacke F, Wree A, Hellberg T, Roderburg C. The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. Int J Mol Sci 2021;22:8569. [PMID: 34445276 DOI: 10.3390/ijms22168569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
22 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 69] [Article Influence: 61.0] [Reference Citation Analysis]
23 Tsoli M, Daskalakis K, Kassi E, Kaltsas G, Tsolakis AV. A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical Tumors. Biology (Basel) 2021;10:580. [PMID: 34201922 DOI: 10.3390/biology10070580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Becker A, Schalin-Jäntti C, Itkonen O. Comparison of Serum and Urinary 5-Hydroxyindoleacetic Acid as Biomarker for Neuroendocrine Neoplasms. J Endocr Soc 2021;5:bvab106. [PMID: 34195530 DOI: 10.1210/jendso/bvab106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Li Y, Wu ZQ, Xu Q, Goyal H, Xu HG. Development and Validation of Novel Nomograms Using Serum Tumor Markers for the Prediction of Preoperative Histologic Grades in Gastroenteropancreatic Neuroendocrine Tumors. Front Oncol 2021;11:681149. [PMID: 34109127 DOI: 10.3389/fonc.2021.681149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Modlin IM, Kidd M, Oberg K, Falconi M, Filosso PL, Frilling A, Malczewska A, Salem R, Toumpanakis C, Laskaratos FM, Partelli S, Roffinella M, von Arx C, Kudla BK, Bodei L, Drozdov IA, Kitz A. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Ann Surg Oncol 2021. [PMID: 34008138 DOI: 10.1245/s10434-021-10021-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
27 Pirasteh A, Lovrec P, Bodei L. Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities. Rev Endocr Metab Disord 2021;22:539-52. [PMID: 33783695 DOI: 10.1007/s11154-021-09631-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
28 Eeckhout K, Van Cotthem K, Guerti K. Evaluation of three commercially available ELISA kits for the determination of chromogranin A. J Immunoassay Immunochem 2021;42:95-105. [PMID: 33043835 DOI: 10.1080/15321819.2020.1830105] [Reference Citation Analysis]
29 Ruhwedel T, Rogasch JMM, Huang K, Jann H, Schatka I, Furth C, Amthauer H, Wetz C. The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers (Basel) 2021;13:635. [PMID: 33562643 DOI: 10.3390/cancers13040635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Cavalcoli F, Rossi RE, Massironi S. Circulating Biochemical Markers of Gastro-Entero-Pancreatic (GEP) Neuroendocrine Neoplasms (NENs). Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_5] [Reference Citation Analysis]
31 Malczewska A, Oberg K, Kos-Kudla B. NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocr Connect 2021;10:110-23. [PMID: 33289691 DOI: 10.1530/EC-20-0417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
32 Hellberg T, Mohr R, Geisler L, Knorr J, Wree A, Demir M, Benz F, Lambrecht J, Loosen SH, Tacke F, Roderburg C, Jann H, Özdirik B. Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. PLoS One 2020;15:e0244504. [PMID: 33382770 DOI: 10.1371/journal.pone.0244504] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Papantoniou D, Grönberg M, Landerholm K, Welin S, Ziolkowska B, Nordvall D, Janson ET. Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2. Endocrine 2021;72:893-904. [PMID: 33244704 DOI: 10.1007/s12020-020-02534-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Baekdal J, Krogh J, Klose M, Holmager P, Langer SW, Oturai P, Kjaer A, Federspiel B, Hilsted L, Rehfeld JF, Knigge U, Andreassen M. Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics (Basel) 2020;10:E881. [PMID: 33138020 DOI: 10.3390/diagnostics10110881] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Tarquini M, Ambrosio MR, Albertelli M, de Souza PB, Gafà R, Gagliardi I, Carnevale A, Franceschetti P, Zatelli MC. A tool to predict survival in stage IV entero-pancreatic NEN. J Endocrinol Invest 2021;44:1185-92. [PMID: 32892316 DOI: 10.1007/s40618-020-01404-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Özdirik B, Stueven AK, Mohr R, Geisler L, Wree A, Knorr J, Demir M, Vucur M, Loosen SH, Benz F, Reiss M, Wiedenmann B, Tacke F, Jann H, Hellberg T, Roderburg C. Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study. J Clin Med 2020;9:E2881. [PMID: 32899973 DOI: 10.3390/jcm9092881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
37 Wu Z, Wang Z, Zheng Z, Bi J, Wang X, Feng Q. Risk Factors for Lymph Node Metastasis and Survival Outcomes in Colorectal Neuroendocrine Tumors. Cancer Manag Res 2020;12:7151-64. [PMID: 32848469 DOI: 10.2147/CMAR.S256723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Papalou O, Peppa M, Kandaraki E, Diamanti-kandarakis E, Nikou G. The Diagnostic Value of Chromogranin A in Neuroendocrine Neoplasms is Potentiated by Clinical Factors and Inflammatory Markers. Endocrines 2020;1:1-12. [DOI: 10.3390/endocrines1010001] [Reference Citation Analysis]
39 Malczewska A, Kos-Kudła B, Kidd M, Drozdov I, Bodei L, Matar S, Oberg K, Modlin IM. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Adv Med Sci 2020;65:18-29. [PMID: 31841822 DOI: 10.1016/j.advms.2019.10.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
40 Novikova O, Department of Cryoendocrinology, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, Sidorenko O, Bozhok G, Bondarenko T, Department of Cryoendocrinology, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, Department of Cryoendocrinology, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine, Department of Cryoendocrinology, Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkiv, Ukraine. Cryopreservation Effect on Chromogranin A Expression in Neonatal Pig Adrenal Cell Culture. Probl Cryobiol Cryomed 2019;29:344-353. [DOI: 10.15407/cryo29.04.344] [Reference Citation Analysis]
41 Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS. PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers (Basel). 2019;11. [PMID: 31795447 DOI: 10.3390/cancers11121902] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
42 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
43 Lim M, Erdman P, Cho S, Mathew A, Fleisher M, Thoren KL. Evaluation of CisBio ELISA for Chromogranin A Measurement. J Appl Lab Med 2019;4:11-8. [PMID: 31639703 DOI: 10.1373/jalm.2018.028027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
44 Kidd M, Drozdov IA, Matar S, Gurunlian N, Ferranti NJ, Malczewska A, Bennett P, Bodei L, Modlin IM. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS One 2019;14:e0218592. [PMID: 31247038 DOI: 10.1371/journal.pone.0218592] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
45 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 12.7] [Reference Citation Analysis]
46 Bílek R, Vlček P, Šafařík L, Michalský D, Novák K, Dušková J, Václavíková E, Widimský J Jr, Zelinka T. Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma. Cancers (Basel) 2019;11:E586. [PMID: 31027285 DOI: 10.3390/cancers11040586] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
47 Matar S, Malczewska A, Oberg K, Bodei L, Aslanian H, Lewczuk-Myślicka A, Filosso PL, Suarez AL, Kolasińska-Ćwikła A, Roffinella M, Kos-Kudła B, Ćwikła JB, Drozdov IA, Kidd M, Modlin IM. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Neuroendocrinology 2020;110:185-97. [PMID: 30995665 DOI: 10.1159/000500202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
48 Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. Endocr Relat Cancer 2019;26:R157-79. [PMID: 30615596 DOI: 10.1530/ERC-18-0354] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
49 Bodei L, Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR. Time for a change and to adopt a novel molecular genomic approach in NETs. Nat Rev Clin Oncol 2019;16:269-70. [PMID: 30809030 DOI: 10.1038/s41571-019-0185-5] [Reference Citation Analysis]
50 Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M, Lupescu I, Dima SO, Buica F, Dumitrascu T, Lungulescu C, Croitoru VM, Tanase A, Negru SM, Gramaticu IM. LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. Acta Endocrinol (Buchar) 2019;15:390-7. [PMID: 32010361 DOI: 10.4183/aeb.2019.390] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 李 梦. Advances in Diagnosis and Treatment of Primary Hepatic Neuroendocrine Neoplasms. ACM 2019;09:225-234. [DOI: 10.12677/acm.2019.93035] [Reference Citation Analysis]
52 Boons G, Vandamme T, Peeters M, Beyens M, Driessen A, Janssens K, Zwaenepoel K, Roeyen G, Van Camp G, Op de Beeck K. Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations. Front Oncol 2018;8:467. [PMID: 30443491 DOI: 10.3389/fonc.2018.00467] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
53 Di Giacinto P, Rota F, Rizza L, Campana D, Isidori A, Lania A, Lenzi A, Zuppi P, Baldelli R. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol 2018;2018:8126087. [PMID: 30057604 DOI: 10.1155/2018/8126087] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 10.5] [Reference Citation Analysis]
54 Corsello A, Di Filippo L, Massironi S, Sileo F, Dolcetta Capuzzo A, Gemma M, Carlucci C, Cusini C, Colombo B, Dallatomasina A, Franchi GM, Corti A, Manzoni MF. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. PLoS One. 2018;13:e0196858. [PMID: 29723285 DOI: 10.1371/journal.pone.0196858] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]